Incretin & Metabolic Receptor Agonists
Retatrutide
Also known as LY3437943
Last reviewed: 2026-11-19
Evidence status & limitations
Phase 2 and later human trials investigate metabolic endpoints; they do not by themselves constitute regulatory approval.
Regulatory status
No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.
Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.
WADA prohibited status: current list and contextKnown risks & open questions
Gastrointestinal symptoms and increased heart rate occurred in trials; long-term and rare risks require follow-up.
Key sources
Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.
Related compounds
- Semaglutide
Same scientific class · A 31-amino-acid chain. · FDA-approved for specific indications
- Tirzepatide
Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications